Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citra Marga Nusaphala Persada Tbk. (CMNP) vs Brigit Biofarmaka Teknologi Tbk. (OBAT) Price & Performance

Citra Marga Nusaphala Persada Tbk.Trade
Brigit Biofarmaka Teknologi Tbk.Trade

Price performance (Past 24H)

Key statistics

Citra Marga Nusaphala Persada Tbk. vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Citra Marga Nusaphala Persada Tbk. trades at Rp1,345 (market cap 9.11T, 96.2K 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp246 (market cap 167.37B, 71K 24h volume). The key difference: Citra Marga Nusaphala Persada Tbk. is far larger — about 54.4× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Citra Marga Nusaphala Persada Tbk. is more actively traded (96.2K versus 71K). Which is the better fit depends on your goals.

CMNPOBAT
Market Cap
9.11T167.37B
Volume
96.2K71K
Lot
962710
Turnover
129.18M17.51M
Average Price
1,342.87246.63
Value
129.18M17.51M
Indicative Equilibrium Price
1,345246
Indicative Equilibrium Volume
21

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

CMNP
View details
OBAT
View details

About Citra Marga Nusaphala Persada Tbk.

PT Citra Marga Nusaphala Persada Tbk (the Company) was established within the framework of the Domestic Investment Law No. 6 of 1968, as amended by Law No. 12 of 1970 based on Notarial Deed No. 58 dated April 13, 1987 of Kartini Muljadi, S.H.The Company derives its revenues primarily from tollgate proceeds, project management fees and, to a lesser extent, from services related to the operations of a toll way system. The Company started commercial operations on March 1990. On June 19th, 1996, the Tanjung Priok – Jembatan Tiga toll road started commercial operations.

Read more on CMNP

About Brigit Biofarmaka Teknologi Tbk.

PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.

Read more on OBAT